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Summary
 
We have previously shown that nonobese diabetic (NOD) mice are selectively deficient in 
 
a/b
 
-T
cell receptor (TCR)
 
1
 
CD4
 
2
 
CD8
 
2
 
 NKT cells, a defect that may contribute to their susceptibility
to the spontaneous development of insulin-dependent diabetes mellitus (IDDM). The role of
NKT cells in protection from IDDM in NOD mice was studied by the infusion of thymocyte
subsets into young female NOD mice. A single intravenous injection of 10
 
6
 
 CD4
 
2/
 
low
 
CD8
 
2
 
 or
CD4
 
2
 
CD8
 
2
 
 thymocytes from female (BALB/c 
 
3 
 
NOD)F1 donors protected intact NOD
mice from the spontaneous onset of clinical IDDM. Insulitis was still present in some recipient
mice, although the cell infiltrates were principally periductal and periislet, rather than the in-
traislet pattern characteristic of insulitis in unmanipulated NOD mice. Protection was not asso-
ciated with the induction of “allogenic tolerance” or systemic autoimmunity. Accelerated
IDDM occurs after injection of splenocytes from NOD donors into irradiated adult NOD re-
cipients. When 
 
a/b
 
-TCR
 
1
 
 and 
 
a/b
 
-TCR
 
2
 
 subsets of CD4
 
2
 
CD8
 
2
 
 thymocytes were trans-
ferred with diabetogenic splenocytes and compared for their ability to prevent the development
of IDDM in irradiated adult recipients, only the 
 
a/b
 
-TCR
 
1
 
 population was protective, confirming
that NKT cells were responsible for this activity. The protective effect in the induced model of
IDDM was neutralized by anti–IL-4 and anti–IL-10 monoclonal antibodies in vivo, indicating
a role for at least one of these cytokines in NKT cell-mediated protection. These results have
significant implications for the pathogenesis and potential prevention of IDDM in humans.
 
N
 
KT cells express cell surface markers of both T cells
(such as the 
 
a/b
 
-TCR) and NK cells (including
NK1.1, CD16, Ly49A, and Ly49C) and appear to play a
role in immunoregulation (for review see reference 1). Recent
evidence has suggested that they may also play a role in the
pathogenesis of insulin-dependent diabetes mellitus (IDDM)
 
1
 
in nonobese diabetic (NOD) mice that spontaneously de-
velop IDDM closely resembling the human disease (2).
Zipris et al. (3) found that thymocytes from young NOD
mice proliferated poorly after stimulation by concanavalin
A or plate-bound anti-CD3 mAb. This peculiarity was
subsequently shown to be associated with decreased IL-2
and IL-4 production. Although addition of IL-2 in vitro
partially corrected this defect, supplementation with IL-4
not only completely normalized in vitro responses, but also
reduced the incidence of spontaneous IDDM of mice
treated
 
 
 
in vivo (4). They concluded that a failure of NOD
thymocytes to produce sufficient IL-4 for the differentia-
tion of regulatory CD4
 
1
 
CD8
 
2
 
 Th2 clones may disrupt the
balance between self-tolerance and autoimmunity resulting
in IDDM. 
A plausible explanation for the decreased levels of IL-4
produced following stimulation of NOD mouse thymocytes
was provided when Gombert et al. (5, 6) and our own
group (7, 8) independently discovered that these mice are
deficient in NKT cells. Gombert et al. (5, 6) reported that
NOD mice have a deficit in the number and functional ca-
pacity of heat stable antigen (HSA)
 
2
 
, CD8
 
2
 
, 
 
a/b
 
-TCR
 
1
 
,
Mel-14
 
2
 
, or CD44
 
1
 
 thymocytes, which display the V
 
b
 
8-
biased TCR repertoire characteristic of NKT cells. The con-
sequence of this deficiency in vivo was demonstrated by the
injection of anti-CD3 mAb. Normally, in vivo stimulation
of NKT cells by anti-CD3 mAb results in appearance of
IL-4 messenger RNA within 30 min of injection followed
 
1
 
Abbreviations used in this paper:
 
 APC, allophycocyanin; BCG, bacillus Cal-
mette-Guerin; DN, double negative; IDDM, insulin-dependent diabetes
mellitus; NOD, nonobese diabetic; RT, room temperature.
 
D.I. Godfrey and A.G. Baxter contributed equally to this work.
  
1048
 
NKT Cells in NOD Mice
 
by a rise in protein production of IL-4 protein peaking at 2 h
(9). Gombert et al. (6) found that the amount of IL-4 pro-
duced in vitro by cells from young NOD mice after anti-CD3
challenge was much lower than that produced by cells from
C57BL/6 mice and similar to the amount produced by
cells from NKT cell–deficient 
 
b
 
2 microglobulin
 
2/2
 
 tar-
geted mutant mice (10). Although there was some increase
in IL-4 production by cells from older NOD mice, the lev-
els remained fourfold lower than controls (6). 
A comparable deficiency in thymic NKT cells in NOD
mice was identified by our group (7, 8) during a multipa-
rameter flow cytometric study of thymic T cell develop-
ment in nine different mouse strains. The results revealed a
three- to sevenfold reduction in the numbers of 
 
a/b
 
-
TCR
 
1
 
CD4
 
2
 
CD8
 
2
 
 (double negative; DN) thymocytes
from NOD mice compared with other nondiabetes-prone
strains. This DN cell population not only shows the V
 
b
 
8-
biased TCR repertoire described above (9, 11), but is
known to secrete large amounts of IL-4 rapidly after activa-
tion in vitro (12). In addition to the thymic defect, spleen
and lymph nodes of NOD mice also had reduced numbers
of 
 
a/b
 
-TCR
 
1
 
DN cells (13). Evidence for the potential rel-
evance of this defect to the pathogenesis of IDDM was ob-
tained by demonstrating that transfer of DN thymocytes,
but not unfractionated thymocytes, from either semialloge-
neic (F1) donors or 35-wk-old syngeneic NOD mice pre-
vented the spontaneous onset of IDDM (13).
These studies prompted two main lines of inquiry. The
first was to determine whether 
 
a/b
 
-TCR
 
1
 
CD4
 
2
 
CD8
 
2
 
(NKT) cells were responsible for the protective activity
within the population of DN thymocytes, which included
both 
 
a/b
 
-TCR
 
1
 
 and 
 
a/b
 
-TCR
 
2
 
 cells. The second goal
was to define the mechanism of action by which these cells
prevented IDDM. 
 
Materials and Methods
 
Mice.
 
Female NOD/Lt//Arc, BALB/c//Arc, and (NOD 
 
3
 
BALB)F1 mice were obtained from the Animal Resources Cen-
tre (Canning Vale, Perth, Australia) and maintained in clean con-
ditions in the Centenary Institute Animal House (Sydney, Austra-
lia). Sentinel mice were tested by serology at four monthly intervals
for the following pathogens: mouse hepatitis virus, rotavirus, ec-
tomelia, mouse cytomegalovirus, polyoma virus, murine adeno-
virus, lymphocytic choriomeningitis virus, mouse pneumonia virus,
reovirus, Sendai virus, Theiler’s murine encephalitis virus, 
 
Bacillus
piliformis
 
, 
 
Mycoplasma pulmonis
 
, 
 
Bordtella bronchiseptica
 
, 
 
Corynebacte-
rium kutscheri,
 
 
 
klebsiella
 
 species, 
 
Pasturella multocide
 
, 
 
Pasturella pneu-
motropica
 
, 
 
Pseudomonas aeruginosa
 
, 
 
Staphylococcus aureus
 
, 
 
Streptococcus
pneumoniae
 
, 
 
Citrobacter freundii,
 
 and 
 
salmonella
 
 species. No mice
tested positive for any of these pathogens. Mice were housed at
21
 
8
 
C and 40% humidity and were fed mouse chow (Barastock,
Melbourne, Australia) and acidified water ad libitum.
 
Isolation of DN Thymocytes. 
 
CD4
 
1
 
 and CD8
 
1
 
 cells were de-
pleted by a 30-min incubation with anti-CD4 (clone RL-172.4)
and anti-CD8 (clone 3.155) supernatants at 4
 
8
 
C followed by a
30-min incubation with rabbit complement (C-six Diagnostics,
Mecquon, WI) at 37
 
8
 
C. Viable cells were recovered over Histo-
paque 1083 (Sigma Chemical Co., Castle Hill, Australia), washed
and labeled with anti-CD4-PE (clone RM4-5; PharMingen, San
Diego, CA), anti-CD8
 
a
 
-allophycocyanin (APC) (clone 53-6.7,
PharMingen), and anti–
 
a/b
 
-TCR–FITC (clone H57-597; Phar-
Mingen). In some experiments, DN cells were further purified
from the depleted population using a FACStarPLUS
 
Ò
 
 (Becton
Dickinson, San Jose, CA) with or without further separation of
DN cells into 
 
a/b
 
-TCR
 
2
 
 and 
 
a/b
 
-TCR
 
1
 
 subsets. Sorted popu-
lations were 98–99.9% pure.
 
Flow Cytometric Analysis.
 
For multiparameter labeling of lym-
phocytes, cells were stained with anti–
 
a/b
 
-TCR–FITC (clone
H57-597; PharMingen), anti-CD4-PE (clone RM4-5; PharMin-
gen), or anti-CD4-biotin (clone CT-CD4; Caltag Laboratories,
San Francisco, CA) and anti-CD8
 
a
 
-APC (clone 53-6.7; Phar-
Mingen). Biotinylated mAbs were detected with streptavidin-conju-
gated Texas red (Molecular Probes, Eugene, OR). For intracellu-
lar cytokine staining, cells were incubated overnight on 24-well
plates that had been previously coated with 10 
 
m
 
g/ml anti-CD3
mAb (KT3) with the addition of 10 
 
m
 
g/
 
m
 
l Brefeldin A (Sigma
Chemical Co.) 3 h after initiation of the culture. The next day,
the cells were surface stained for CD4 and CD8 expression. The
cells were then fixed with 4% paraformaldehyde for 20 min and
stained for cytokines using anti–IL-4–PE (clone 11B11; Phar-
Mingen) and anti–IFN-
 
g
 
–FITC (clone XMG1.2; PharMingen)
in 0.5% saponin (Sigma Chemical Co.). Analysis was performed
on a FACStarPLUS
 
Ò
 
 (Becton Dickinson, San Jose, CA).
 
Adoptive Transfer of Thymocytes.
 
DN thymocyte subpopulations
were tested for efficacy in two models of IDDM. In the first
model, prediabetic 3–4-wk-old female unmanipulated NOD/Lt
mice were injected intravenously with 1.0 
 
3 
 
10
 
6
 
–2.0 
 
3 
 
10
 
6
 
 thy-
mocytes (either unfractionated or fractions prepared as described
above) in 200 
 
m
 
l of PBS or with 200 
 
m
 
l of PBS alone. Recipients
were then bled from 12–35 wk of age at two weekly intervals for
blood glucose estimations. Mice were declared diabetic if two
blood glucose readings 
 
.
 
11.1 mM were obtained or if death oc-
curred immediately after a single reading 
 
.
 
11.1 mM. 
In the second model, nondiabetic 10–12-wk-old female gamma-
irradiated (700 R) NOD/Lt mice were injected intravenously
with 3.8 
 
3 
 
10
 
5
 
–2.0 
 
3 
 
10
 
6
 
 thymocytes (prepared as described
above) in 200 
 
m
 
l of PBS, or with 200 
 
m
 
l of PBS alone immedi-
ately followed by 2.0 
 
3 
 
10
 
7
 
 splenocytes from female diabetic
NOD mice in 200 
 
m
 
l of PBS. Mice were bled for blood glucose
estimations 3 and 4 wk later and were declared diabetic after a
single reading 
 
.
 
11.1 mM. The end point was determined by ei-
ther the onset of IDDM or at 4 wk.
As lymphoid tissue from young NOD mice contained insuffi-
cient numbers of 
 
a/b
 
-TCR
 
1
 
DN cells, cells for transfer were de-
rived from (NOD 
 
3 
 
BALB/c)F1 mice, which have much greater
numbers and are partially isogenic with NOD mice (13). 
Blood glucose estimations were performed on retroorbital
venous blood samples by the glucose oxidase technique using
Glucofilm test strips (Bayer Australia, Pymble, Australia) assayed
on a Glucometer M
 
1
 
 meter (Bayer Diagnostics, Pymble, Australia).
 
Neutralization of IL-4 and IL-10 by mAb Treatment In Vivo.
 
mAbs 11B11 rat anti–mouse IL-4 (IgG1) and JES5-2A5 rat anti–
mouse IL-10 (IgG1; gifts of John Abrams, DNAX, Palo Alto, CA)
were grown as ascites in pristane-primed (1.0 ml/mouse intra-
peritoneally, 2, 6, 10, 14 tetramethylpentadecane 98%; Aldrich
Chemical Company, Milwaukee, WI) BALB/c-
 
nu/nu mice. As-
cites supernatants and rat IgG (Sigma Chemical Co.) were puri-
fied on a protein G–Sepharose column (Pharmacia Biotech,
Uppsala, Sweden), dialyzed against PBS, and concentrated by os-
mosis using Aquacide (Calbiochem, La Jolla, CA). Mice were in-
jected intraperitoneally on the day of transfer (day 0), and days 1,1049 Hammond et al.
3, and 6 after transfer with either 0.5 mg 11B11 together with 0.5
mg JES5-2A5, or 1.0 mg rat IgG or PBS.
Skin Grafts. Donor BALB/c mice were killed by cervical dis-
location and the tails removed. The tail skin was incised longitu-
dinally, stripped from the underlying tissues, and placed in a ster-
ile petri dish, dermis down, on a bed of filter paper moistened in
PBS and then cut into segments z1 cm2. Recipient NOD mice
were anesthetized with 1.25–1.75 mg Ketamine (Apex Laborato-
ries, St. Mary’s, Australia) and 0.25–0.35 mg Xylazine (Bayer
Australia) in PBS subcutaneously. The superficial layers of the
skin over the graft site on the flanks of the recipients were re-
moved with surgical scissors to prepare a bloodless vascular field
for the graft. The graft was held in place with petroleum jelly im-
pregnated gauze and a bandage of adhesive surgical tape. Postop-
erative analgesia was achieved with 0.02 mg buprenorphine
(Reckitt and Coleman, Bristol, UK) injected subcutaneously im-
mediately before surgery. 8 d after grafting, the dressing was re-
moved and grafted mice were placed in individual cages for mon-
itoring of graft survival.
Insulitis Scoring. Pancreata were either fixed in 10% formalin
in saline and paraffin embedded or embedded in Tissue-Tek
OCT compound (Miles, Elkhart, IN) and frozen on a mixture of
ethanol and dry ice. Three serial 6-mm sections were cut at each
of three levels 100 mm apart and stained with hematoxylin and
eosin. Each islet was examined at 3100 and given a score from 0
to 4 in which 0 represented a noninfiltrated islet and 4 repre-
sented complete infiltration or a “burned-out” islet. The insulitis
score for each mouse was calculated by expressing the total of the
scores as a percentage of the sum of the maximum possible scores.
Hematocrit Measurement and Direct Coombs’ Test. 75  ml of blood
were drawn up into a heparinized capillary tube (Becton Dickin-
son, Franklin Lakes, NJ) and centrifuged at 1,600 g for 30 min.
The height of the column of packed red cells was divided by the
total height of the column of blood and expressed as a percentage.
10 ml of packed cells were resuspended in 5 ml PBS with 0.3%
bovine serum albumin, washed, and resuspended in 1 ml of the
same solution. For two aliquots, 100 ml of each sample were
placed in 96-well round-bottomed plates (Nunc, Copenhagen,
Denmark) with three serial one-half dilutions. 10 ml of 10 mg/ml
polyclonal goat anti–mouse IgG-Fc (Jackson ImmunoResearch
Laboratories, Austin, TX) were added to one of the sets of dilu-
tions and the plates were vortexed gently and incubated at 378C
for 3 h. Wells in which the cells collected in a button at the bot-
tom were recorded as negative, whereas those in which the cells
remained spread over the surface of the well were recorded as
positive.
Assessment of Antinuclear Antibodies. Sera were assessed for bind-
ing to HEp-2 slides (Sanofi Diagnostics Pasteur Inc., Chaska,
MN). Slides were incubated in PBS for 10 min. Sera diluted in
PBS (starting concentration 1:100) were incubated on the slides at
room temperature (RT) for 30 min in a moist chamber. Slides
were then washed three times for 5 min in PBS and incubated for
30 min at RT with 50 mg/ml FITC-conjugated rat anti–mouse
IgG gamma chain–specific antisera (Southern Biotechnology As-
sociates, Birmingham, AL). Slides were again washed three times
for 5 min with PBS, mounted with polyvinyl alcohol mounting
media (Sanofi Diagnostics Pasteur Inc.), and examined on a fluo-
rescence microscope (Leica Mikoskopie, Postfach, Germany).
Control sera were obtained from bacillus Calmette-Guerin (BCG)-
treated NOD mice previously demonstrated to produce antinu-
clear antibodies and BALB/c-nu/nu mice.
Detection of Glomerular Immune Complex Deposits. Kidneys were
embedded in Tissue-Tek OCT compound (Miles) and frozen for
histological analysis. 6-mm sections were cut on a cryostat (Mi-
crom, Waldorf, Germany), mounted on microscope sides, air
dried, acetone fixed for 10 min, and stored at 2808C in an air-
tight bag containing silica desiccant. When slides were stained,
they were thawed to RT, fixed in acetone for a further 5 min,
and blocked with 4% FCS (CSL, Melbourne, Australia). Sections
were stained with goat anti–mouse C3c polyclonal IgG (Nordic
Immunological Laboratories, Tilburg, Holland) at a 1:10 dilution
in PBS for 45 min. Slides were then washed three times in PBS,
cover slipped with polyvinyl alcohol mounting media (Sanofi Di-
agnostics Pasteur Inc.), and examined on a fluorescence micro-
scope (Leica Mikoskopie, Postfach, Germany).
ELISA for IL-4 and IFN-g. IL-4 and IFN-g were detected
by sandwich ELISA. The capture antibody 11B11 (anti–IL-4) or
AN18 (anti–IFN-g) was bound to round-bottomed microtiter
plates that were then blocked with 2% FCS in PBS at 378C for 1 h.
Sample supernatants and cytokine standards were titrated and in-
cubated for 2 h on the plates that were then washed and the de-
tection layer (BVD6-biotin for IL-4 or XMG-biotin for IFN-g)
was added. Bound detection antibody was detected with strepta-
vidin-horseradish peroxidase (Jackson ImmunoResearch, West
Baltimore, PA). The substrate used was 2,29 azino-bis(3-ethyl-
benzthiazoline)-6 sulfonic acid (Sigma Chemical Co.) and results
were determined by optical density scanning on a Labsystems
Multiscan Multisoft (Helsinki, Finland).
Statistical Analysis. Qualitative differences between samples
were examined using the fourfold table (x2) test unless the ex-
pected value in any cell was 5 or less, in which case the Fisher’s
exact test was used. Quantitative differences between samples
were compared with the Mann Whitney U (rank sum) test.
Results
DN Thymocytes Prevent Spontaneous IDDM in NOD
Mice. Intracellular cytokine staining of NK1.1-expressing
C57BL/6 mice revealed that about half of the IL-4–pro-
ducing a/b-TCR1NK1.11 thymocytes are DN and half
are CD41CD82 (data not shown). Since NOD mice do
not express the NK1.1 allelic marker and a/bTCR1
NK1.11 cells comprise a much larger proportion of DN
thymocytes than of CD41CD82 thymocytes in C57BL/6
mice, the a/b-TCR1DN phenotype was used as a surro-
gate marker of NKT cells in NOD mice. In addition to
confirming that young female NOD mice are deficient in
a/b-TCR1DN thymocytes (7, 8, 13), it was found that
very few IL-4–producing cells could be identified in anti-
CD3–stimulated short-term cultures of NOD thymocytes
(Fig. 1). The role of NKT cells in protection from IDDM
was therefore investigated by using DN thymocytes from
(BALB 3 NOD)F1 donors because we had previously
demonstrated that these mice contained normal numbers of
a/b-TCR1DN thymocytes (13) and subsequently found
that a large proportion of their thymocytes secrete IL-4 af-
ter short-term anti-CD3 stimulation (Fig. 1).
In a series of experiments, different numbers (1–2 3
106/mouse) of DN thymocytes from (NOD 3 BALB)F1
donors were injected intravenously into 3–4-wk-old fe-
male NOD recipients (Fig. 2). Administration of DN thy-
mocytes conferred substantial resistance to IDDM with
only 2/19 of the recipients developing diabetes, compared1050 NKT Cells in NOD Mice
with controls that either received whole thymocytes (13/
19, P ,0.0001, x2 fourfold table test) or PBS (12/21, P
,0.001, x2 fourfold table test). For these experiments, two
methods of enrichment of DN thymocytes were used. In
the first, complement-mediated depletion of anti-CD4 and
anti-CD8 antibody-binding cells served to produce a pop-
ulation consisting of CD42/lowCD82 thymocytes with an
overall purity .97%. The second method involved com-
plement-mediated depletion followed by FACSÒ to ex-
clude the CD4low population and purify only the DN pop-
ulation with .99% purity. Both sources of thymocytes
protected recipients from the development of diabetes, in-
dicating that protective cells were contained within the
DN population. The numbers of cells transferred, as well as
the relative proportion of a/b-TCR1 cells within each in-
oculum, varied between experiments; consequently, the total
numbers of a/b-TCR1CD42/lowCD82 or a/b-TCR1DN
thymocytes injected varied from z105–106/mouse. The
only two treated mice to develop IDDM were injected
with the lowest number (1.12 3 105) of a/b-TCR1DN
thymocytes, consistent with a minimum of z1.5 3 105 a/
b-TCR1DN thymocytes being required for protection.
Histological analysis of the pancreata of mice surviving
to the termination of the experiment was performed. Al-
though there was no significant difference between the in-
sulitis scores of treated mice and nondiabetic control mice,
the pattern of insulitis in the treated mice was qualitatively
different and could be subdivided into three distinct pat-
terns. 7/15 mice had florid periductal and/or periislet lym-
phoid collections with intact islets. One third of the mice
had no signs of insulitis or other infiltrates at all, whereas
the remainder had intraislet infiltrates qualitatively similar
to those normally found in nondiabetic untreated mice
(Fig. 3). 
IDDM Protection by DN Thymocytes Is Not Associated with
Tolerance to Alloantigen. The preceding experiments indi-
cated that protective cells reside in the DN population of
thymocytes, but did not tell us whether or not a/b-TCR1
cells mediate this effect as g/d T cells, NK cells, B cells, and
macrophages are also found within this population. Conse-
quently, the expression of semiallogeneic major histocom-
patibility products by antigen-presenting cells could have
led to protection by inducing “allogenic tolerance”, as
Bendelac et al. (14) reported that the induction of neonatal
tolerance to F1 splenocytes resulted in significant protec-
tion from both insulitis and diabetes. To examine the out-
come of treatment with DN thymocytes on the allogeneic
responses of young NOD recipients, 4-wk-old female NOD
mice were injected with 3.0 3 106 complement-depleted
(BALB 3 NOD)F1 thymocytes (.96% CD42/lowCD82;
39.9% a/b-TCR1; equates to 106 a/b-TCR1CD42/low
CD82 thymocytes) and were grafted 2 mo later with
BALB/c tail skin grafts. The tail skin grafts on all six recip-
ients of DN thymocytes were rejected by day 8. Five of
seven grafts on PBS-treated control recipients rejected by
day 8, and the remaining two by day 14. Although these
results failed to indicate a role for allogenic tolerance in
protection against IDDM in this model, they did not ex-
clude the possibility that protection was mediated by the
transfer of antigen-presenting cells, which could exert a
mild immunostimulatory action (15). 
Subfractionation of DN Thymocytes in Induced IDDM.
To dissect the mechanism of protection in more detail, a
more rapid assay was adopted involving the induction of
diabetes within 3–4 wk by injection of 2.0 3 107 spleno-
cytes from spontaneously diabetic NOD donors into irradi-
ated nondiabetic adult NOD recipients (16). This model is
relatively robust since it is refractory to many treatments re-
ported to protect intact NOD mice from the onset of
spontaneous IDDM, such as the administration of CFA or
BCG (data not shown).
Figure 1. Expression of the ab-TCR on (A and B), and IL-4 produc-
tion by (C and D) DN thymocytes from NOD (A and C) and (NOD 3
BALB)F1 (B and D) mice.
Figure 2. Diabetes-free survival of female NOD mice after injection at
3–4 wk of age with DN thymocytes (dotted line), unfractionated thy-
mocytes (solid line), or PBS (dashed line). 1051 Hammond et al.
Varying numbers (5.0 3 105–2.0 3 106) of DN thy-
mocytes from nondiabetes prone (NOD 3 BALB)F1 do-
nors were injected together with diabetogenic splenocytes
intravenously into 10–12-wk-old irradiated nondiabetic fe-
male NOD recipients. 3/14 (21%) recipients of DN thy-
mocytes subsequently developed IDDM, compared with
7/12 and 7/10 recipients given PBS or unfractionated thy-
mocytes, respectively (64%, P ,0.05, x2 fourfold table test;
Table 1). The numbers of cells transferred, as well as the
relative proportion of a/b-TCR1 cells within each inocu-
lum, varied between experiments so that the total numbers
of a/b-TCR1CD42/lowCD82 thymocytes injected ranged
from z3 3 104 to 9 3 105/mouse. The only treated mice
to develop IDDM received the lowest numbers of a/b-
TCR1CD42/lowCD82 thymocytes, which were below the
threshold of 1.5 3 105 identified previously. Two addi-
tional treatment groups were included in this series of ex-
periments. In the first (Table 1, group 2) recipients were
given 5 3 105–1 3 106 FACSÒ sorted a/b-TCR2DN thy-
mocytes resulting in development of IDDM in 10/15 of
them (P ,0.05, c.f., DN thymocyte–treated group, Fisher’s
exact test). Members of the other group (Table 1, group
3) received 4 3 105–5 3 105 a/b-TCR1DN thymocytes
and 1/6 developed diabetes (NS, c.f., DN thymocyte–
treated group, Fisher’s exact test). Thus, protection medi-
ated by DN thymocytes resides in the a/b-TCR1DN pop-
ulation, excluding a role for g/d T cells, NK cells, and pro-
fessional antigen-presenting cells in the process.
The Role of Cytokine Production in NKT Cell–mediated Pro-
tection. Pancreatic lymph nodes were removed at the ter-
mination of some of the experiments involving use of the
induced model of IDDM described above (Table 1, exper-
iments 2 and 3). Lymphocytes obtained from this source
were stimulated for 2 d with immobilized anti-CD3 mAb
and ELISAs for IL-4 and IFN-g were performed on the su-
pernatants. There were no consistent differences in the
elicited cytokine responses between cells from the various
groups of mice (data not shown). As NKT cells might have
exerted their effect at a site other than the draining lymph
node, a combination of anti–IL-4 and anti–IL-10 mAb was
administered systemically to irradiated recipients that had
been given a protective inoculum of these cells. Three of
five recipients of diabetogenic splenocytes alone developed
IDDM. 15 mice divided into three groups of five were
treated with 106 DN thymocytes (99.9% pure, 15.3% a/b-
TCR1) in addition to the splenocytes. One of five mice in
the group given PBS and none of five mice treated with
control rat IgG developed IDDM, whereas four of five
mice treated with anti–IL-4 and anti–IL-10 mAb did so (P
,0.05, c.f., combined control groups, Fisher’s exact test;
Table 2), indicating that IL-4 and/or IL-10 are important
for NKT cell–mediated protection in this system.
Effect of DN Thymocyte Transfer on Systemic Autoimmu-
nity. Some therapies for IDDM, which are associated with
response class switching, have been shown to induce a lu-
pus-like syndrome in treated NOD mice, despite exerting a
protective effect against diabetes (e.g., BCG; reference 17).
Consequently, all of the protected NOD mice treated with
DN thymocytes at 3–4 wk were examined at 35 wk for
signs of systemic autoimmunity. None of them had a he-
matocrit below 50%, nor were any positive for Coombs’
autoantibodies. Moreover, there was no significant differ-
Figure 3. Typical histological appearance at 35 wk of hematoxylin and eosin–stained islets from nondiabetic female NOD mice injected at 3–4 wk of
age with DN thymocytes (A, 3400; B, 3200) or unfractionated thymocytes (C, 3400). 1052 NKT Cells in NOD Mice
ence in the incidence or level of antinuclear autoantibodies
between the groups treated with DN thymocytes, unfrac-
tionated thymocytes, or PBS. Finally, only 1/17 DN thy-
mocyte–treated mice had any evidence of C3c deposition
in the renal glomeruli, and in this case it was minimal, be-
ing detected at a similar level to that seen in 4/25 control
NOD mice. In other words, delayed induction of systemic
autoimmunity did not occur in mice treated with DN thy-
mocytes. 
Discussion
The work described here has led to identification of a
population of thymocytes that can protect prediabetic
NOD mice from developing IDDM. This effect is likely to
be due to NKT cells for several reasons. First, NKT cells
were contained within the protective population. Although
NKT cells are often defined by the coexpression of cell sur-
face markers characteristic of both T cells (e.g., a/b-TCR)
and NK cells (e.g., NK1.1), NK1.1 can not be used for this
purpose in strains that do not express this allelic marker, in-
cluding NOD mice. Moreover none of the other proposed
markers such as CD44, CD22, and CD122 adequately de-
fine NKT cells in C57BL/6 mice, thereby making it diffi-
cult to distinguish and separate NKT cells from a popula-
tion of whole thymocytes with any degree of certainty. For
this reason, we have focussed on a/b-TCR1DN thy-
mocytes, which are known to be highly enriched for NKT
cells and can be readily identified in most strains of mice.
After transfer of subpopulations of thymocytes into young
NOD mice, the spontaneous onset of IDDM was pre-
vented both by CD42/lowCD82 thymocytes, as well as by
FACSÒ-sorted DN thymocytes in which the CD4low thy-
mocytes had been excluded (Fig. 2). 
Table 1. Protection from Induced IDDM by DN Thymocytes
Experiment DN No. Sorted Purity a/b Percent a/b DN No. Diabetic (Percent)
Group 1
1 2.0 3 106 No 81.0 55 8.9 3 105 0/5 (0)
2 5.0 3 105 Yes 99.8 19 9.4 3 104 0/3 (0)
3 5.0 3 105 Yes 99.9 15 7.4 3 104 1/3 (33)
4 5.0 3 105 Yes 99.9 8.9 3.4 3 104 2/3 (67)
Group total 3/14 (21)
Group 2
2 1.0 3 106 Yes 99.8 – – 2/3 (67)
3 1.0 3 106 Yes 99.9 – – 2/3 (67)
4 1.0 3 106 Yes 99.6 – – 2/3 (67)
2 5.0 3 105 Yes 99.8 – – 1/2 (50)
3 5.0 3 105 Yes 99.9 – – 2/2 (100)
4 5.0 3 105 Yes 99.6 – – 1/2 (50)
Group total 10/15 (67)
Group 3
2 5.0 3 105 Yes 99.2 – 4.9 3 105 0/2 (0)
3 5.0 3 105 Yes 97.1 – 5.0 3 105 0/2 (0)
4 3.8 3 105 Yes 98.8 – 3.8 3 105 1/2 (50)
Group total 1/6 (17)
Group 4
1 2.0 3 106 No 4.2* 53 4.5 3 104 2/3 (67)
2 1.0 3 106 No 2.3* 19 4.3 3 103 1/2 (50)
3 1.0 3 106 No 3.4* 25 8.6 3 103 3/3 (100)
4 1.0 3 106 No 2.8* 16 4.4 3 103 1/2 (50)
Group total 7/10 (70)
Group 5
Group total (experiments 1–4) 7/12 (58)
Group 1, DN thymocyte recipients; group 2, a/b-TCR2 DN thymocyte recipients; group 3, a/b-TCR1 DN thymocyte recipients; group 4, un-
fractionated thymocytes; group 5, PBS recipients.
*Percent DN of unfractionated thymocytes.1053 Hammond et al.
The second reason why the protective activity of the
thymocyte subsets used here is likely to be due to NKT
cells is related to the fact that protection observed in the in-
duced model of IDDM resided within the a/b-TCR1
population and not the a/b-TCR2 (non–T cell) popula-
tion of DN thymocytes (Table 1). Therefore, this finding
not only excluded involvement of NK or g/d cells in pro-
tection mediated by the DN thymocyte fraction, but also
ruled out a protective role for professional APCs that could
have exerted an immunostimulatory effect similar to that of
treatment with BCG, CFA, IL-2, or Poly(I:C) (15). More-
over, many preventative therapies for IDDM in intact
NOD mice, including immunostimulatory agents such as
CFA and BCG, are ineffective in the induced model used
here, whereas DN thymocytes remained effective, high-
lighting the potency of the a/b-TCR1 DN cells in protec-
tion from IDDM.
The third reason why the protective activity of DN thy-
mocytes is likely to be due to NKT cells is related to the
known functional properties of these cells. Depletion of
NKT cells with either anti-NK1.1 or anti-Va14 mAb in
C57BL/6.lpr mice, C3H.gld mice, or (NZB 3 NZW)F1
mice exacerbated autoimmune disease (18, 19), whereas
disease onset was delayed by adoptive transfer of NKT cells
into preautoimmune C57BL/6.lpr recipients (19). Further-
more, clones expressing the invariant Va14Ja281 TCR
characteristic of NKT cells have been reported that sup-
press delayed-type hypersensitivity after skin painting with
2,4-dinitrobenzene sulfonate (20) and responses to tumors
in vivo and in vitro (21). NKT cells also appear to be re-
sponsible for mediating anterior chamber-associated im-
mune deviation after intraocular administration of low
doses of foreign antigen (22). 
The protective activity of transferred NKT cells in NOD
mice appears to be mediated by the Th2-associated cyto-
kines IL-4 and/or IL-10 since neutralization of IL-4 and
IL-10 by mAb treatment during the first week after NKT
cell transfer inhibited protection by these cells (Table 2).
Significantly, the effect of NKT cells described here is con-
sistent with the action of IL-4 and/or IL-10 in other exper-
imental systems involving NOD mice. For example, ad-
ministration of IL-4 to NOD mice reduced the incidence
of spontaneous IDDM (4), whereas NOD mice expressing
IL-4 under an insulin promoter were also completely pro-
tected from insulitis and diabetes (23). Rabinovich et al.
(24) reported that IL-10 together with IL-4 reduced islet
cell graft destruction in diabetic NOD mice, whereas ac-
cording to Pennline et al. (25), administration of IL-10
alone to NOD mice reduced the incidence of spontaneous
IDDM. Paradoxically, an accelerated form of diabetes oc-
curred in NOD mice expressing very high levels of IL-10
under an insulin promoter (26, 27), although in non-NOD
strains, islet expression of IL-10 did not cause diabetes but
was associated with extensive periislet infiltrates similar to
those seen in some NKT cell–treated NOD mice described
here (28; Fig. 3).
The results reported here, when taken in conjunction
with previous data, shed new light on the pathogenesis of
IDDM in NOD mice. Although an unopposed Th2 antiis-
let response can, under some circumstances, lead to IDDM
in NOD mice (26, 27), a more typical scenario of sponta-
neous disease in this strain appears to be a period of mixed
intraislet cytokine responses (29, 30) that become polarized
over time towards either a Th2 or Th1 phenotype (31, 32).
Polarization to a Th1 response probably results in more
rapid progression to IDDM because the “destructive” insu-
litis, which occurs in NOD mice at high risk of IDDM, is
associated with a higher frequency of cells producing IFN-g
and a lower frequency of cells producing IL-4 than the
“nondestructive” insulitis, which occurs in CFA-treated fe-
male NOD mice and male NOD mice (33). Moreover, the
destructive antiislet response in diabetic NOD mice is usu-
ally accompanied by the production of, and is dependent
on, Th1-associated cytokines because administration of
anti–IFN-g mAb reduces both the severity of insulitis and
the incidence of diabetes in cyclophosphamide accelerated
(34), adoptively transferred (35), and spontaneous IDDM (25). 
These findings lead to the concept of “plasticity” of the
early, mixed-cytokine phase of insulitis. On the one hand,
IL-12 can precipitate IDDM in young NOD mice (36) and
cyclophosphamide treatment, which also leads to acceler-
ated onset of IDDM in these mice, is associated with the
rapid induction of IL-12 gene expression in vivo (37). On
the other hand, NKT cell therapy may prevent onset of
IDDM by exerting an opposite effect on the pattern of cy-
tokine production within the intraislet infiltrate. Thus, the
directed production of IL-4 and/or IL-10 by NKT cells
may redress the emerging polarization of the pattern of in-
traislet cytokine production resulting in a more balanced
cytokine profile associated with a slower rate of islet de-
struction.
We therefore propose that the deficiency of NKT cells
in NOD mice contributes to the pathogenesis of IDDM by
permitting a disproportionate Th1 response to emerge. The
prevention of IDDM, which occurs when approximately
normal numbers of these cells are replaced or their function
is simulated by the administration of IL-4 (4), represents
one of very few examples of prevention of IDDM by cor-
recting an underlying immunological defect in NOD mice,
the only other well-documented instance being correction
of the unusual MHC class II haplotype of NOD mice by
Table 2. Role of IL-4 and IL-10 in NKT Cell–mediated 
Protection from Induced IDDM
Group
Cells transferred
Treatment Diabetic Splenocytes NKT
1 2.0 3 107 0 PBS 3/5 (60)
2 2.0 3 107 1.0 3 106 Rat IgG 0/5 (0)
3 2.0 3 107 1.0 3 106 PBS 1/5 (20)
4 2.0 3 107 1.0 3 106 aIL-4/aIL-10 4/5 (80)*
*P ,0.05, group 4 versus groups 2 and 3, Fisher’s exact test.1054 NKT Cells in NOD Mice
transgenesis (38–42). It is important to note that the immu-
nomodulatory activity of NKT cells reported here can in-
terfere with an established effector response as illustrated by
their efficacy in the induced model of IDDM, whereas a
similar approach based on the use of islet-specific Th2 T
cell clones did not appear to be as effective (43, 44).
The ultimate aim of studying models such as the NOD
mouse is to translate the findings into clinical practice.
NKT cells have been identified in humans and, like their
counterpart in the mouse, they express a limited diversity
of TCRs. Thus, they express the Va24, JaQ, and Vb11
chains, which are homologous to the Va14, Ja281, and
Vb8.2 chains used by mouse NKT cells (45–49) and pro-
duce high levels of IL-4 after stimulation through the TCR
(50, 51). It will therefore be important to study NKT cell
numbers and function in patients with IDDM and their
families to determine whether a defect similar to that found
in NOD mice occurs. If it does, such a defect would have
profound implications, both for our understanding of the
pathogenesis of IDDM, as well for prospective preventative
therapy.
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